Endocyte Inc. (NASDAQ:ECYT) saw unusually-strong trading volume on Tuesday . Approximately 146,674 shares traded hands during mid-day trading, an increase of 34% from the previous session’s volume of 109,368 shares.The stock last traded at $3.06 and had previously closed at $3.18.

Several equities analysts recently weighed in on ECYT shares. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Endocyte in a research note on Wednesday, May 4th. Cowen and Company reaffirmed a “buy” rating on shares of Endocyte in a research note on Wednesday, May 4th. Zacks Investment Research downgraded Endocyte from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.15.

The firm has a 50-day moving average of $3.26 and a 200-day moving average of $3.43. The company’s market capitalization is $128.57 million.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. During the same period last year, the company earned ($0.26) EPS. On average, analysts forecast that Endocyte Inc. will post ($1.10) EPS for the current fiscal year.

In other Endocyte news, insider Philip S. Low acquired 11,375 shares of Endocyte stock in a transaction dated Tuesday, May 10th. The stock was acquired at an average cost of $3.52 per share, for a total transaction of $40,040.00. Following the completion of the transaction, the insider now owns 206,606 shares in the company, valued at approximately $727,253.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.